基于pNIPAm的pH和热敏共聚物凝用于疏水性和疏水性药物输送
Anandhu Mohan1, Madhappan Santhamoorthy2, Thi Tuong Vy Phan3,4
1Department of Nano Science and Technology Convergence, General Graduate School, Gachon University, 1342 Seongnam-Daero, Sujeong-gu, Seongnam-si 13120, Gyeonggi-do, Republic of Korea.
Gels (Basel, Switzerland)
|March 27, 2024
概括
开发了一种新型的双pH和温度响应的水凝,用于控制药物输送. 这种生物相容的水凝系统有效释放水和水友药物,显示了先进治疗应用的潜力.
科学领域:
- 聚合物科学和生物材料工程 聚合物科学和生物材料工程
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 开发响应刺激的水凝对于有针对性的药物输送至关重要.
- 水凝提供了一个有前途的平台,用于控制释放疏水性和亲水性药物.
- 双刺激响应系统提高药物管理的精度和有效性.
研究的目的:
- 为了合成和表征一种新型的胺功能化聚 ((N-异烯酸烯胺-co-glycidyl甲基酸盐) 共聚合物水凝 (pNIPAm-co-pGMA-Mela).
- 为了评估水凝的双重pH和温度响应的药物释放行为,使用模型疏水性 (易布洛芬) 和疏水性 (5-甲) 药物.
- 评估开发的水凝系统的体外生物相容性和血液相容性,用于潜在的药物输送应用.
主要方法:
- N-异烯酸胺 (NIPAm) 和甘甲酸盐 (GMA) 的联合聚合,随后进行胺功能化.
- 使用诸如1H NMR,FTIR,SEM,泽塔潜力和粒子大小分析等技术进行表征.
- 在不同的pH (4.0,7.4) 和温度 (25°C,37°C,45°C) 条件下进行体外药物释放研究;通过MTT测定和血液相容性测试评估生物相容性.
主要成果:
- 在pNIPAm-co-pGMA-Mela水凝成功合成和特征.
- 水凝表现出显著的双刺激反应释放,在pH值为4.0和45°C时实现了约100%的布洛芬和5-甲释放.
- 在体外研究证实了水凝的生物相容性和血液相容性.
结论:
- 开发的pNIPAm-co-pGMA-Mela水凝具有出色的双重pH和温度反应能力.
- 这种水凝系统是一个有希望的候选人,可以控制水和水药物的输送.
- 该材料的生物相容性和血液相容性支持其在先进的药物输送应用中的潜在用途.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
01:23Modified-Release Drug Delivery Systems: Classification
315
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
315
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
01:11Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222